WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of GERON CORP (GERN)

Name GERON CORP
Year low 1.35
Year High 5.03
Symbol GERN
Last trade 1.37
Percentage change -2.84
Volume 926,183
Media Volume (3m) 885,462
PE Ratio N/A
EPS -0.728
Market Cap 181
Media fatt 2
Trend fatt trend fatt graph for GERON CORP
Media net income -93
Trend net income trend net income for GERON CORP
P / E P / E graph for GERON CORP - 0 points 0
EPS EPS graph for GERON CORP - 0 points 0
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for GERON CORP - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for GERON CORP - 11 points 11
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for GERON CORP - 11 points 11
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for GERON CORP - 0 points 0
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for GERON CORP - 0 points 0
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for GERON CORP - 8 points 8
NET INC1/NET INC3 net inc1/net inc3 graph for GERON CORP - 4 points 4
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for GERON CORP - 5 points 5
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for GERON CORP - 0 points 0
. . graph for GERON CORP -  points
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for GERON CORP - 2 points 2
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for GERON CORP - 2 points 2
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for GERON CORP - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for GERON CORP - 0 points 0
. . graph for GERON CORP -  points
SELL HOLD BUY SELL           HOLD          BUY graph for GERON CORP - 0 points 0
SINTESE 43

GRAPHS

max price logarithm graph for GERON CORP based on no conditions max volume linear graph for GERON CORP based on no conditions

News

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Non-Small Cell Lung Cancer (May 03 - reuters) Geron Corporation Reports 2012 First Quarter Financial Results and Highlights (May 02 - reuters) Neostem's Comeback In The Making (Apr 27 - reuters) BioTime: Backed By Dubious Stock Promoters (Apr 26 - reuters) Geron Announces Conference Call to Discuss First Quarter 2012 Financial Results (Apr 25 - reuters) 5 Stocks Under $10 Set to Spike Higher (Apr 20 - reuters) Geron to Present at the Future Leaders in the Biotech Industry Conference (Apr 17 - reuters) BioTime Is Running Out Of Time - Short-Sell Idea (Apr 11 - reuters) Geron Announces Presentations at AACR Annual Meeting (Mar 30 - reuters) Microcap Biotech Stocks Accumulated By The World's Largest Money Managers (Mar 28 - reuters) Geron Appoints V. Bryan Lawlis to Board of Directors (Mar 15 - reuters) Geron Corporation Reports Fourth Quarter and Annual 2011 Financial Results (Mar 07 - reuters) Thinking Of Spring: Tulips And Cancer Stem Cell Mania (Mar 05 - reuters) Geron Announces Conference Call to Discuss Fourth Quarter and Annual 2011 Financial Results (Feb 28 - reuters) Geron Corp: Why I Decided To Take A Flyer On This $2 Biotech Stock (Feb 28 - reuters) Geron to Present at the Citi Global Health Care Conference (Feb 22 - reuters) Groundbreaking Technology And Buyout Potential Has InVivo Therapeutics On The Move (Feb 15 - reuters) The InVivo Effect (Feb 14 - reuters) Verastem Valued At Premium, InVivo Worth Even More On Innovative Therapy (Feb 10 - reuters) Geron to Present at the BIO CEO & Investor Conference (Feb 08 - reuters) Geron: Mea Culpa (Feb 06 - reuters) Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Breast Cancer (Feb 02 - reuters) More Biotech Lessons Learned From JPM 2012 (Jan 13 - reuters) Ariad: This Bio-Pharma May Deliver Big Returns (Jan 11 - reuters) Geron Corporation Appoints Graham Cooper as Chief Financial Officer (Jan 05 - reuters) Osiris Shows No Reason To Invest In Stem Cell Ideas (Jan 05 - reuters) Geron to Present at the J.P. Morgan Healthcare Conference (Jan 05 - reuters) Micro-Cap Biotech Stocks Legendary Fund Managers Are Accumulating (Jan 04 - reuters) The Worst Health Care Stocks of 2011 (Dec 30 - reuters) Bullish Ideas: Short-Sellers Think These Cash-Rich Companies Have More Upside (Dec 28 - reuters) Geron Is Now A Bargain Buy (Dec 27 - reuters) Health Care's Worst Stocks 2011: Dendreon (Dec 24 - reuters) Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Lung Cancer (Dec 22 - reuters) Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story (Dec 19 - reuters) Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer (Dec 12 - reuters) NeoStem Might Be A Hidden Gem (Dec 07 - reuters) NovaBay May Be In The Right Place At The Right Time With An Answer For Antibiotic Resistance (Dec 02 - reuters) Noteworthy Insider Buys In The Healthcare Sector Last Week (Nov 29 - reuters) Market Volatility = Biotech Opportunity (Nov 22 - reuters) Trade Ideas From Last Week's Big Biotech News Movers (Nov 21 - reuters) Tomorrow's Monster Stock (Nov 17 - reuters) Geron Dumps Stem Cells For Cancer Focus (Nov 17 - reuters) 3 Biotechs Beating the Market (Nov 17 - reuters) The Market Just Crushed My Stock! (Nov 16 - reuters) Other Stem Cell Players Ready To Fill Void Left By Geron (Nov 16 - reuters) Geron Exits Stem Cells To Focus On Oncology (Nov 16 - reuters) Geron's Shift Opens The Door Wide For InVivo (Nov 16 - reuters) UPDATE 1-Geron shares drop on stem cell retreat (Nov 15 - reuters) The Beneficiaries of Geron's Exit From Stem Cell Therapy (Nov 15 - reuters) Geron's Stem Cell Bust Leaves Investors Holding the Bag (Nov 15 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY